GLP-1 Drugs Do Not Increase Pancreatitis Risk in High-Risk Diabetes Patients
Large retrospective analysis of 4.5+ million members finds GLP-1 analogues do not increase recurrent pancreatitis risk in diabetic patients with prior pancreatitis or elevated lipase.
Quick Facts
What This Study Found
GLP-1 analogues were not associated with increased recurrent pancreatitis risk in diabetic patients with prior pancreatitis or elevated lipase, in a cohort of >4.5 million members.
Key Numbers
How They Did This
Retrospective cohort analysis from a large health maintenance organization (>4.5 million members) comparing pancreatitis recurrence in GLP-1 users vs non-users among high-risk patients.
Why This Research Matters
Pancreatitis concerns have limited GLP-1 prescribing. Showing safety even in the highest-risk patients removes a major barrier to appropriate use.
The Bigger Picture
This joins accumulating evidence that the initial pancreatitis safety signal with GLP-1 drugs was likely spurious, supporting their broader clinical use.
What This Study Doesn't Tell Us
Retrospective observational design. Despite large database, the subgroup with prior pancreatitis may still be relatively small. Could not capture unreported mild pancreatitis episodes.
Questions This Raises
- ?Can GLP-1 drugs now be prescribed without pancreatitis disclaimers?
- ?Should current prescribing guidelines be updated to remove pancreatitis warnings?
Trust & Context
- Key Stat:
- 4.5M+ member safety data No increased pancreatitis recurrence risk with GLP-1 drugs even in high-risk patients
- Evidence Grade:
- Large retrospective cohort — strong real-world safety evidence from a massive population.
- Study Age:
- Published in 2026; addresses a long-debated GLP-1 safety concern.
- Original Title:
- Glucagon-Like Peptide-1 Analogues and the Risk of Recurrent Pancreatitis in Diabetic Patients With History of Pancreatitis or Elevated Lipase: Retrospective Cohort Analysis.
- Published In:
- Diabetes/metabolism research and reviews, 42(1), e70116 (2026)
- Authors:
- Calvarysky, Bronya, Gal, Yaara, Kushnir, Shiri, Turjeman, Adi, Shochat, Tzippy, Dotan, Idit, Diker Cohen, Talia
- Database ID:
- RPEP-14927
Evidence Hierarchy
Frequently Asked Questions
Do GLP-1 drugs cause pancreatitis?
This large study of over 4.5 million people — including high-risk patients with prior pancreatitis — found no increased pancreatitis risk with GLP-1 drugs. Early concerns appear to have been unfounded.
Can I take GLP-1 drugs if I had pancreatitis before?
This study suggests GLP-1 drugs do not increase recurrent pancreatitis risk even in patients with prior episodes. However, discuss your specific history with your doctor.
Read More on RethinkPeptides
Related articles coming soon.
Cite This Study
https://rethinkpeptides.com/research/RPEP-14927APA
Calvarysky, Bronya; Gal, Yaara; Kushnir, Shiri; Turjeman, Adi; Shochat, Tzippy; Dotan, Idit; Diker Cohen, Talia. (2026). Glucagon-Like Peptide-1 Analogues and the Risk of Recurrent Pancreatitis in Diabetic Patients With History of Pancreatitis or Elevated Lipase: Retrospective Cohort Analysis.. Diabetes/metabolism research and reviews, 42(1), e70116. https://doi.org/10.1002/dmrr.70116
MLA
Calvarysky, Bronya, et al. "Glucagon-Like Peptide-1 Analogues and the Risk of Recurrent Pancreatitis in Diabetic Patients With History of Pancreatitis or Elevated Lipase: Retrospective Cohort Analysis.." Diabetes/metabolism research and reviews, 2026. https://doi.org/10.1002/dmrr.70116
RethinkPeptides
RethinkPeptides Research Database. "Glucagon-Like Peptide-1 Analogues and the Risk of Recurrent ..." RPEP-14927. Retrieved from https://rethinkpeptides.com/research/calvarysky-2026-glucagonlike-peptide1-analogues-and
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.